{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:24:00Z","timestamp":1770434640102,"version":"3.49.0"},"reference-count":81,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Arterial stiffness (AS) is considered an independent predictor of cardiovascular disease\n(CVD) events. Among lipid lowering drugs, statins have a beneficial effect on AS, independent of their\nhypolipidaemic effect. Based on 3 meta-analyses and other studies, this effect is compound- and doserelated.\nPotent statins at high doses are more effective than less powerful statins. Ezetimibe (\u00b1 statin)\nalso seems to decrease AS in patients with dyslipidaemia. Fibrates have no effect on AS. Proprotein\nconvertase subtilisin\/kexin type 9 (PCSK9) inhibitors have data that beneficially affect all AS risk factors,\nsuggesting a beneficial effect on artery compliance. However, there is no direct measurement of\ntheir effect on AS indices. In patients with dyslipidaemia, prescribing high dose statins (\u00b1 ezetimibe)\nwill not only decrease low-density lipoprotein cholesterol levels but also improve AS (in addition to\nother effects). This effect on AS may contribute to the observed reduction in vascular events.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161117666190121102323","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T12:58:05Z","timestamp":1576673885000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?"],"prefix":"10.2174","volume":"18","author":[{"given":"Andromachi","family":"Reklou","sequence":"first","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asterios","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Athyros","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000348620","volume":"1","author":"Avolio A.","year":"2013","unstructured":"Avolio A.; Arterial stiffness. Pulse 2013,1,14-28","journal-title":"Pulse"},{"key":"ref=2","volume":"7","author":"Said M.A.","year":"2018","unstructured":"Said M.A.; Eppinga R.N.; Lipsic E.; Verweij N.; van der Harst P.; Relationship of arterial stiffness index and pulse pressure with cardiovascular disease and mortality. J Am Heart Assoc 2018,7","journal-title":"J Am Heart Assoc"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYP.0000000000000033","volume":"66","author":"Townsend R.R.","year":"2015","unstructured":"Townsend R.R.; Wilkinson I.B.; Schiffrin E.L.; Recommendations for improving and standardizing vascular research on arterial stiffness: A scientific statement from the American heart association. Hypertension 2015,66,698-722","journal-title":"Hypertension"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","volume":"55","author":"Vlachopoulos C.","year":"2010","unstructured":"Vlachopoulos C.; Aznaouridis K.; Stefanadis C.; Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 2010,55,1318-1327","journal-title":"J Am Coll Cardiol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.jacc.2014.09.060","volume":"64","author":"Redheuil A.","year":"2014","unstructured":"Redheuil A.; Wu C.O.; Kachenoura N.; Proximal aortic distensibility is an independent predictor of all-cause mortality and incident CV events: The MESA study. J Am Coll Cardiol 2014,64,2619-2629","journal-title":"J Am Coll Cardiol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2015.05.007","volume":"241","author":"Vlachopoulos C.","year":"2015","unstructured":"Vlachopoulos C.; Xaplanteris P.; Aboyans V.; The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: Endorsed by the association for research into arterial structure and physiology (ARTERY) society. Atherosclerosis 2015,241,507-532","journal-title":"Atherosclerosis"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fcvm.2018.00064","volume":"5","author":"Bonarjee V.V.","year":"2018","unstructured":"Bonarjee V.V.; Arterial stiffness: a prognostic marker in coronary heart disease. Available methods and clinical application. Front Cardiovasc Med 2018,5,64","journal-title":"Front Cardiovasc Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/1471-2458-11-266","volume":"11","author":"Garcia-Ortiz L.","year":"2011","unstructured":"Garcia-Ortiz L.; Ramos-Delgado E.; Recio-Rodriguez J.I.; Peripheral and central arterial pressure and its relationship to vascular target organ damage in carotid artery, retina and arterial stiffness. Development and validation of a tool. The Vaso risk study. BMC Public Health 2011,11,266","journal-title":"BMC Public Health"},{"key":"ref=9","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/621437","volume":"2014","author":"Jani\u0107 M.","year":"2014","unstructured":"Jani\u0107 M.; Lunder M.; Sabovi\u010d M.; Arterial stiffness and cardiovascular therapy. BioMed Res Int 2014,2014","journal-title":"BioMed Res Int"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10641963.2017.1411498","volume":"40","author":"D\u2019elia L.","year":"2018","unstructured":"D\u2019elia L.; La Fata E.; Iannuzzi A.; Rubba P.O.; Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clin Exp Hypertens 2018,40,601-608","journal-title":"Clin Exp Hypertens"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2016.11.073","volume":"227","author":"Upala S.","year":"2017","unstructured":"Upala S.; Wirunsawanya K.; Jaruvongvanich V.; Sanguankeo A.; Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol 2017,227,338-341","journal-title":"Int J Cardiol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2016.03.010","volume":"212","author":"Sahebkar A.","year":"2016","unstructured":"Sahebkar A.; Pe\u0107in I.; Tedeschi-Reiner E.; Derosa G.; Maffioli P.; Reiner \u017d.; Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. Int J Cardiol 2016,212,160-168","journal-title":"Int J Cardiol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ajh\/hps098","volume":"26","author":"Kanaki A.I.","year":"2013","unstructured":"Kanaki A.I.; Sarafidis P.A.; Georgianos P.I.; Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013,26,608-616","journal-title":"Am J Hypertens"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5551\/jat.2683","volume":"17","author":"Fassett R.G.","year":"2010","unstructured":"Fassett R.G.; Robertson I.K.; Ball M.J.; Geraghty D.P.; Sharman J.E.; Coombes J.S.; Effects of atorvastatin on arterial stiffness in chronic kidney disease: A randomised controlled trial. J Atheroscler Thromb 2010,17,235-241","journal-title":"J Atheroscler Thromb"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.117.09023","volume":"70","author":"Sarafidis P.A.","year":"2017","unstructured":"Sarafidis P.A.; Loutradis C.; Karpetas A.; Ambulatory pulse wave velocity is a stronger predictor of cardiovascular events and all-cause mortality than office and ambulatory blood pressure in hemodialysis patients. Hypertension 2017,70,148-157","journal-title":"Hypertension"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.ajkd.2007.03.003","volume":"49","author":"Dogra G.","year":"2007","unstructured":"Dogra G.; Irish A.; Chan D.; Watts G.; A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007,49,776-785","journal-title":"Am J Kidney Dis"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2010.12.041","volume":"215","author":"Lunder M.","year":"2011","unstructured":"Lunder M.; Jani\u0107 M.; Habjan S.; Sabovi\u010d M.; Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males--a pilot study. Atherosclerosis 2011,215,446-451","journal-title":"Atherosclerosis"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1365-2125.2010.03745.x","volume":"70","year":"2010","unstructured":"Wallace SM1 M\u00e4ki-Pet\u00e4j\u00e4 KM, Cheriyan J, et al. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br J Clin Pharmacol 2010,70,799-806","journal-title":"Br J Clin Pharmacol"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5551\/jat.20008","volume":"21","author":"Stoner L.","year":"2014","unstructured":"Stoner L.; Faulkner J.; Lowe A.; Should the augmentation index be normalized to heart rate? J Atheroscler Thromb 2014,21,11-16","journal-title":"J Atheroscler Thromb"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.plefa.2012.11.008","volume":"88","author":"Iketani T.","year":"2013","unstructured":"Iketani T.; Takazawa K.; Yamashina A.; Effect of eicosapentaenoic acid on central systolic blood pressure. Prostaglandins Leukot Essent Fatty Acids 2013,88,191-195","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.atherosclerosis.2014.10.004","volume":"237","author":"Sunbul M.","year":"2014","unstructured":"Sunbul M.; Agirbasli M.; Durmus E.; Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis 2014,237,490-493","journal-title":"Atherosclerosis"},{"key":"ref=22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17040460","volume":"17","author":"Villela-Nogueira C.A.","year":"2016","unstructured":"Villela-Nogueira C.A.; Leite N.C.; Cardoso C.R.; Salles G.F.; NAFLD and increased aortic stiffness: Parallel or common physiopathological mechanisms? Int J Mol Sci 2016,17","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/1570161116666171205105402","volume":"16","author":"Katsiki N.","year":"2018","unstructured":"Katsiki N.; Imprialos K.; Vlachopoulos C.; Editorial: Arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease: Links with cardiovascular risk and effects of drug treatment. Curr Vasc Pharmacol 2018,16,401-404","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1570161115666170630122833","volume":"16","author":"Mitsiou E.","year":"2018","unstructured":"Mitsiou E.; Boutari C.; Kotsis V.; Effect of low (5 mg) vs. high (20-40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension. Curr Vasc Pharmacol 2018,16,393-400","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijcard.2018.08.088","volume":"274","author":"Elffers T.W.","year":"2019","unstructured":"Elffers T.W.; Trompet S.; de Mutsert R.; Borderline Q-waves in individuals without overt cardiovascular disease: Relations with adiposity, subclinical atherosclerosis and vascular stiffness. Int J Cardiol 2019,274,331-336","journal-title":"Int J Cardiol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","volume":"77","author":"Palombo C.","year":"2016","unstructured":"Palombo C.; Kozakova M.; Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol 2016,77,1-7","journal-title":"Vascul Pharmacol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.jacc.2012.12.028","volume":"61","author":"Raggi P.","year":"2013","unstructured":"Raggi P.; Epicardial adipose tissue as a marker of coronary artery disease risk. J Am Coll Cardiol 2013,61,1396-1397","journal-title":"J Am Coll Cardiol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1161\/ATVBAHA.108.170316","volume":"28","author":"Apovian C.M.","year":"2008","unstructured":"Apovian C.M.; Bigornia S.; Mott M.; Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008,28,1654-1659","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2459\/JCM.0b013e3283657c96","volume":"14","author":"Koumaras C.","year":"2013","unstructured":"Koumaras C.; Katsiki N.; Athyros V.G.; Karagiannis A.; Metabolic syndrome and arterial stiffness: the past, the present and the future. J Cardiovasc Med (Hagerstown) 2013,14,687-689","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1017\/S0029665112000092","volume":"71","author":"de Heredia F.P.","year":"2012","unstructured":"de Heredia F.P.; Gomez-Martinez S.; Marcos A.; Obesity, inflammation and the immune system. Proc Nutr Soc 2012,71,332-338","journal-title":"Proc Nutr Soc"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3349\/ymj.2012.53.2.258","volume":"53","author":"Park S.","year":"2012","unstructured":"Park S.; Lakatta E.G.; Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J 2012,53,258-261","journal-title":"Yonsei Med J"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.ajpath.2013.01.010","volume":"182","author":"Hajjar D.P.","year":"2013","unstructured":"Hajjar D.P.; Gotto A.M.; Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. Am J Pathol 2013,182,1474-1481","journal-title":"Am J Pathol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1517\/14728222.11.9.1143","volume":"11","author":"Tziomalos K.","year":"2007","unstructured":"Tziomalos K.; Athyros V.G.; Karagiannis A.; Mikhailidis D.P.; Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007,11,1143-1160","journal-title":"Expert Opin Ther Targets"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/01.CIR.89.6.2519","volume":"89","author":"Egashira K.","year":"1994","unstructured":"Egashira K.; Hirooka Y.; Kai H.; Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994,89,2519-2524","journal-title":"Circulation"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","volume":"95","author":"O\u2019Driscoll G.","year":"1997","unstructured":"O\u2019Driscoll G.; Green D.; Taylor R.R.; Simvastatin, an HMG-coenzyme reductase inhibitor, improves endothelial function within 1 month. Circulation 1997,95,1126-1131","journal-title":"Circulation"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/01.CIR.99.3.354","volume":"99","author":"Koh K.K.","year":"1999","unstructured":"Koh K.K.; Cardillo C.; Bui M.N.; Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999,99,354-360","journal-title":"Circulation"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2004.03.052","volume":"94","author":"Lu T.M.","year":"2004","unstructured":"Lu T.M.; Ding Y.A.; Leu H.B.; Yin W.H.; Sheu W.H.; Chu K.M.; Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004,94,157-161","journal-title":"Am J Cardiol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0021-9150(00)00733-4","volume":"157","author":"Alonso R.","year":"2001","unstructured":"Alonso R.; Mata P.; De Andres R.; Villacastin B.P.; Martinez-Gonzalez J.; Badimon L.; Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 2001,157,423-429","journal-title":"Atherosclerosis"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM199502233320801","volume":"332","author":"Treasure C.B.","year":"1995","unstructured":"Treasure C.B.; Klein J.L.; Weintraub W.S.; Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995,332,481-487","journal-title":"N Engl J Med"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1161\/01.CIR.99.25.3227","volume":"99","author":"Dupuis J.","year":"1999","unstructured":"Dupuis J.; Tardif J.C.; Cernacek P.; Theroux P.; Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999,99,3227-3233","journal-title":"Circulation"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.amjcard.2005.06.057","volume":"96","author":"Dupuis J.","year":"2005","unstructured":"Dupuis J.; Tardif J.C.; Rouleau J.L.; Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol 2005,96,1207-1213","journal-title":"Am J Cardiol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMsa063904","volume":"355","author":"Murad F.","year":"2006","unstructured":"Murad F.; Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006,355,2003-2011","journal-title":"N Engl J Med"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1161\/01.CIR.0000089190.95415.9F","volume":"108","author":"Szmitko P.E.","year":"2003","unstructured":"Szmitko P.E.; Wang C.; Weisel R.D.; De Almeida J.R.; Anderson T.J.; Verma S.; New markers of inflammation and endothelial cell activation. Circulation 2003,108,1917-1923","journal-title":"Circulation"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI200524459","volume":"115","author":"Hare J.M.","year":"2005","unstructured":"Hare J.M.; Stamler J.S.; NO\/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005,115,509-517","journal-title":"J Clin Invest"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00380-004-0793-5","volume":"20","author":"Matsuo T.","year":"2005","unstructured":"Matsuo T.; Iwade K.; Hirata N.; Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 2005,20,8-12","journal-title":"Heart Vessels"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/157016107781024091","volume":"5","author":"Dilaveris P.","year":"2007","unstructured":"Dilaveris P.; Giannopoulos G.; Riga M.; Synetos A.; Stefanadis C.; Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007,5,227-237","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"Ridker P.M.","year":"2016","unstructured":"Ridker P.M.; From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res 2016,118,145-156","journal-title":"Circ Res"},{"key":"ref=48","first-page":"69","volume":"33","author":"Lv S.","year":"2015","unstructured":"Lv S.; Liu Y.; Zou Z.; The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 2015,33,69-76","journal-title":"Clin Exp Rheumatol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","volume":"17","author":"Li G.M.","year":"2018","unstructured":"Li G.M.; Zhao J.; Li B.; The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev 2018,17,215-225","journal-title":"Autoimmun Rev"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00228-006-0238-4","volume":"63","author":"Efrati S.","year":"2007","unstructured":"Efrati S.; Averbukh M.; Dishy V.; Faygenzo M.; Friedensohn L.; Golik A.; The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007,63,113-121","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1476-5381.2012.02106.x","volume":"169","author":"Colucci R.","year":"2013","unstructured":"Colucci R.; Fornai M.; Duranti E.; Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1. Br J Pharmacol 2013,169,554-566","journal-title":"Br J Pharmacol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1089\/152308602762197443","volume":"4","author":"Hanna I.R.","year":"2002","unstructured":"Hanna I.R.; Taniyama Y.; Sz\u00f6cs K.; Rocic P.; Griendling K.K.; NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 2002,4,899-914","journal-title":"Antioxid Redox Signal"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/HYPERTENSIONAHA.109.133710","volume":"54","author":"Briones A.M.","year":"2009","unstructured":"Briones A.M.; Rodr\u00edguez-Criado N.; Hernanz R.; Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009,54,142-149","journal-title":"Hypertension"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2016.05.039","volume":"251","author":"Tissier F.","year":"2016","unstructured":"Tissier F.; Mallem Y.; Goanvec C.; A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits. Atherosclerosis 2016,251,70-77","journal-title":"Atherosclerosis"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.HYP.26.1.2","volume":"26","author":"O\u2019Rourke M.","year":"1995","unstructured":"O\u2019Rourke M.; Mechanical principles in arterial disease. Hypertension 1995,26,2-9","journal-title":"Hypertension"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5455\/aim.2013.21.12-15","volume":"21","author":"Kamberi L.S.","year":"2013","unstructured":"Kamberi L.S.; Gorani D.R.; Hoxha T.F.; Zahiti B.F.; Aortic compliance and stiffness among severe longstanding hypertensive and non-hypertensive. Acta Inform Med 2013,21,12-15","journal-title":"Acta Inform Med"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1185\/030079903125002225","volume":"19","author":"Tsiara S.","year":"2003","unstructured":"Tsiara S.; Elisaf M.; Mikhailidis D.P.; Early vascular benefits of statin therapy. Curr Med Res Opin 2003,19,540-556","journal-title":"Curr Med Res Opin"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.5551\/jat.9548","volume":"18","author":"Kurobe H.","year":"2011","unstructured":"Kurobe H.; Aihara K.; Higashida M.; Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011,18,1080-1089","journal-title":"J Atheroscler Thromb"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5551\/jat.2378","volume":"17","author":"Yagi S.","year":"2010","unstructured":"Yagi S.; Akaike M.; Aihara K.; Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010,17,173-180","journal-title":"J Atheroscler Thromb"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2008.05.026","volume":"203","author":"Nakagami H.","year":"2009","unstructured":"Nakagami H.; Osako M.K.; Takami Y.; Vascular protective effects of ezetimibe in apoE-deficient mice. Atherosclerosis 2009,203,51-58","journal-title":"Atherosclerosis"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1567-5688(15)50007-X","volume":"17","author":"Averna M.","year":"2015","unstructured":"Averna M.; The effect of ezetimibe on NAFLD. Atheroscler Suppl 2015,17,27-34","journal-title":"Atheroscler Suppl"},{"key":"ref=62","first-page":"265","volume":"Nov 23; 17","author":"Wu N.Q.","year":"2018","unstructured":"Wu N.Q.; Guo Y.L.; Zhu C.G.; Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis 2018,Nov 23; 17,265","journal-title":"Lipids Health Dis"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5551\/jat.10835","volume":"19","author":"Tamaki N.","year":"2012","unstructured":"Tamaki N.; Ueno H.; Morinaga Y.; Shiiya T.; Nakazato M.; Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012,19,532-538","journal-title":"J Atheroscler Thromb"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5551\/jat.1578","volume":"17","author":"Hiramitsu S.","year":"2010","unstructured":"Hiramitsu S.; Ishiguro Y.; Matsuyama H.; The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010,17,106-114","journal-title":"J Atheroscler Thromb"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.5551\/jat.4465","volume":"17","author":"Miyashita Y.","year":"2010","unstructured":"Miyashita Y.; Endo K.; Saiki A.; Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2010,17,1070-1076","journal-title":"J Atheroscler Thromb"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jacc.2007.04.076","volume":"50","author":"M\u00e4ki-Pet\u00e4j\u00e4 K.M.","year":"2007","unstructured":"M\u00e4ki-Pet\u00e4j\u00e4 K.M.; Booth A.D.; Hall F.C.; Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007,50,852-858","journal-title":"J Am Coll Cardiol"},{"key":"ref=67","first-page":"49","volume":"25","author":"Marais A.D.","year":"2004","unstructured":"Marais A.D.; Familial hypercholesterolaemia. Clin Biochem Rev 2004,25,49-68","journal-title":"Clin Biochem Rev"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.metabol.2017.04.007","volume":"74","author":"Katsiki N.","year":"2017","unstructured":"Katsiki N.; Athyros V.G.; Mikhailidis D.P.; Mantzoros C.; Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism 2017,74,43-46","journal-title":"Metabolism"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cpt.1138","volume":"104","author":"Vincent J.","year":"2018","unstructured":"Vincent J.; Lipid lowering therapy for atherosclerotic cardiovascular disease: It is not so simple. Clin Pharmacol Ther 2018,104,220-224","journal-title":"Clin Pharmacol Ther"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.hjc.2018.05.003","volume":"60","author":"Vlachopoulos C.","year":"2019","unstructured":"Vlachopoulos C.; Koutagiar I.; Terentes-Printzios D.; Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidaemias. Hellenic J Cardiol 2019,60(2),124-128","journal-title":"Hellenic J Cardiol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.hjc.2016.03.002","volume":"57","author":"Rallidis L.S.","year":"2016","unstructured":"Rallidis L.S.; Lekakis J.; PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions. Hellenic J Cardiol 2016,57,86-91","journal-title":"Hellenic J Cardiol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","volume":"216","author":"Cariouabc B.","year":"2011","unstructured":"Cariouabc B.; Maya C.; Costetab P.; Clinical aspects of PCSK9. Atherosclerosis 2011,216,258-265","journal-title":"Atherosclerosis"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrcardio.2017.75","volume":"14","author":"Wu H.","year":"2017","unstructured":"Wu H.; Ballantyne C.M.; Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nat Rev Cardiol 2017,14,385-386","journal-title":"Nat Rev Cardiol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","volume":"38","author":"Bernelot Moens S.J.","year":"2017","unstructured":"Bernelot Moens S.J.; Neele A.E.; Kroon J.; PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J 2017,38,1584-1593","journal-title":"Eur Heart J"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","volume":"248","author":"Cheng J.M.","year":"2016","unstructured":"Cheng J.M.; Oemrawsingh R.M.; Garcia-Garcia H.M.; PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016,248,117-122","journal-title":"Atherosclerosis"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1024\/0301-1526\/a000689","volume":"47","author":"Gebauer K.","year":"2018","unstructured":"Gebauer K.; Reinecke H.; PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Vasa 2018,47,165-176","journal-title":"Vasa"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2016.01.019","volume":"176","author":"Puri R.","year":"2016","unstructured":"Puri R.; Nissen S.E.; Somaratne R.; Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of global assessment of plaque regression with a pcsk9 antibody as measured by intravascular ultrasound (GLAGOV). Am Heart J 2016,176,83-92","journal-title":"Am Heart J"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3949\/ccjm.84.s4.01","volume":"84","author":"Nissen S.E.","year":"2017","unstructured":"Nissen S.E.; Nicholls S.J.; Results of the GLAGOV trial. Cleve Clin J Med 2017,84(12),1-5","journal-title":"Cleve Clin J Med"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/nutrit\/nux047","volume":"75","author":"Cicero A.F.","year":"2017","unstructured":"Cicero A.F.; Colletti A.; Bajraktari G.; Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev 2017,75,731-767","journal-title":"Nutr Rev"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1874192401812010029","volume":"12","author":"Reklou A.","year":"2018","unstructured":"Reklou A.; Doumas M.; Imprialos K.; Stavropoulos K.; Patoulias D.; Athyros V.G.; Reduction of vascular inflammation, ldl-c, or both for the protection from cardiovascular events? Open Cardiovasc Med J 2018,12,29-40","journal-title":"Open Cardiovasc Med J"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/HJH.0000000000000141","volume":"32","author":"Reklou A.","year":"2014","unstructured":"Reklou A.; Lazaridis A.; Nikolaidou B.; Kadiltzoglou P.; Doumas M.; Macro and microcirculation damage and incident hypertension: Predictors of progression? J Hypertens 2014,32,1154","journal-title":"J Hypertens"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T15:52:06Z","timestamp":1579881126000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169194\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161117666190121102323","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}